Stephen Denis Preston

Stephen Denis Preston

Auto-generated profile, based on publicly available information

Stephen Denis Preston

Department of Histopathology, Royal Papworth Hospital, Cambridge Biomedical Campus Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2008 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
RWRoy O. Weller
Roy O. Weller
MSMalavika Subash
Malavika Subash
SPStephen D. Preston
Stephen D. Preston
IMIngrid Mazanti
Ingrid Mazanti
RCRoxana O. Carare
Roxana O. Carare

1 September 2015 in Cardiovascular Pathology
Verified
Journal Article
Open access
JSJames R. Stone
James R. Stone
PBPatrick Bruneval
Patrick Bruneval
AAAnnalisa Angelini
Annalisa Angelini
GBGiovanni Bartoloni
Giovanni Bartoloni
CBCristina Basso
Cristina Basso
JVJohn P. Veinot
John P. Veinot
Inflammatory diseases of the aorta include routine atherosclerosis, aortitis, periaortitis, and atherosclerosis with excessive inflammatory responses, such as inflammatory atherosclerotic aneurysms. The nomenclature and histologic features of these disorders are reviewed and discussed. In addition, diagnostic criteria are provided to distinguish between these disorders in surgical pathology specimens. An initial classification scheme is provided for aortitis and periaortitis based on the pattern of the inflammatory infiltrate: granulomatous/giant cell pattern, lymphoplasmacytic pattern, mixed inflammatory pattern, and the suppurative pattern. These inflammatory patterns are discussed in relation to specific systemic diseases including giant cell arteritis, Takayasu arteritis, granulomatosis with polyangiitis (Wegener's), rheumatoid arthritis, sarcoidosis, ankylosing spondylitis, Cogan syndrome, Behçet's disease, relapsing polychondritis, syphilitic aortitis, and bacterial and fungal infections.

1 May 2016 in Cardiovascular Pathology
Verified
Journal Article
Closed access
MHMarc K. Halushka
Marc K. Halushka
AAAnnalisa Angelini
Annalisa Angelini
GBGiovanni Bartoloni
Giovanni Bartoloni
CBCristina Basso
Cristina Basso
LBLubov Batoroeva
Lubov Batoroeva
AWAllard C. van der Wal
Allard C. van der Wal

28 March 2003 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Closed access
PDF file
SPS. D. Preston
S. D. Preston
PSP. V. Steart
P. V. Steart
AWA. Wilkinson
A. Wilkinson
JNJ. A. R. Nicoll
J. A. R. Nicoll
RWR. O. Weller
R. O. Weller

13 October 2009 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
RWRoy O Weller
Roy O Weller
SPStephen D Preston
Stephen D Preston
MSMalavika Subash
Malavika Subash
RCRoxana Octavia Carare
Roxana Octavia Carare
Amyloid is deposited in the walls of arteries and capillaries as cerebral amyloid angiopathy (CAA) in the brains of older individuals and of those with Alzheimer disease (AD). CAA in AD reflects an age-related failure of elimination of amyloid-beta (Aβ) from the brain along perivascular lymphatic drainage pathways. In the absence of conventional lymphatic vessel in the brain, interstitial fluid and solutes drain from the brain to cervical lymph nodes along narrow basement membranes in the walls of capillaries and arteries, a pathway that is largely separate from the cerebrospinal fluid. In this review we focus on the pathology and pathogenesis of CAA, its role in the aetiology of AD and its impact on immunotherapy for AD. The motive force for lymphatic drainage of the brain appears to be generated by arterial pulsations. Failure of elimination of Aβ along perivascular pathways coincides with a reduction in enzymic degradation of Aβ, reduced absorption of Aβ into the blood and age-related stiffening of artery walls that appears to reduce the motive force for lymphatic drainage. Reduced clearances of Aβ and CAA are associated with the accumulation of insoluble and soluble Aβs in the brain in AD and the probable loss of homeostasis of the neuronal environment due to retention of soluble metabolites within the brain. Tau metabolism may also be affected. Immunotherapy has been successful in removing insoluble plaques of Aβ from the brain in AD but with little effect on cognitive decline. One major problem is the increase in CAA in immunised patients that probably prevents the complete removal of Aβ from the brain. Increased knowledge of the physiology and structural and genetic aspects of the lymphatic drainage of Aβ from the brain will stimulate the development of therapeutic strategies for the prevention and treatment of AD.

21 November 2017 in Circulation
Verified
Journal Article
Open access
PDF file
CHCharaka Hadinnapola
Charaka Hadinnapola
MBMarta Bleda
Marta Bleda
MHMatthias Haimel
Matthias Haimel
NSNicholas Screaton
Nicholas Screaton
ASAndrew Swift
Andrew Swift
PYPatrick Yong
Patrick Yong
Background: Pulmonary arterial hypertension (PAH) is a rare disease with an emerging genetic basis. Heterozygous mutations in the gene encoding the bone morphogenetic protein receptor type 2 ( BMPR2 ) are the commonest genetic cause of PAH, whereas biallelic mutations in the eukaryotic translation initiation factor 2 alpha kinase 4 gene ( EIF2AK4 ) are described in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. Here, we determine the frequency of these mutations and define the genotype-phenotype characteristics in a large cohort of patients diagnosed clinically with PAH. Methods: Whole-genome sequencing was performed on DNA from patients with idiopathic and heritable PAH and with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis recruited to the National Institute of Health Research BioResource–Rare Diseases study. Heterozygous variants in BMPR2 and biallelic EIF2AK4 variants with a minor allele frequency of <1:10 000 in control data sets and predicted to be deleterious (by combined annotation-dependent depletion, PolyPhen-2, and sorting intolerant from tolerant predictions) were identified as potentially causal. Phenotype data from the time of diagnosis were also captured. Results: Eight hundred sixty-four patients with idiopathic or heritable PAH and 16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis were recruited. Mutations in BMPR2 were identified in 130 patients (14.8%). Biallelic mutations in EIF2AK4 were identified in 5 patients with a clinical diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. Furthermore, 9 patients with a clinical diagnosis of PAH carried biallelic EIF2AK4 mutations. These patients had a reduced transfer coefficient for carbon monoxide (K co ; 33% [interquartile range, 30%–35%] predicted) and younger age at diagnosis (29 years; interquartile range, 23–38 years) and more interlobular septal thickening and mediastinal lymphadenopathy on computed tomography of the chest compared with patients with PAH without EIF2AK4 mutations. However, radiological assessment alone could not accurately identify biallelic EIF2AK4 mutation carriers. Patients with PAH with biallelic EIF2AK4 mutations had a shorter survival. Conclusions: Biallelic EIF2AK4 mutations are found in patients classified clinically as having idiopathic and heritable PAH. These patients cannot be identified reliably by computed tomography, but a low K co and a young age at diagnosis suggests the underlying molecular diagnosis. Genetic testing can identify these misclassified patients, allowing appropriate management and early referral for lung transplantation.